Screener
Exagen Inc. XGN Q2 2026 earnings
Reported August 4, 2026 · Before market open
Revenue$19.9MBeat by $2.1M
EPS-$0.13Beat by $0.06
Revenue estimate$17.8M
EPS estimate-$0.19
“We continue to advance Exagen's unique mission to bring clarity to autoimmune disease. Second quarter financial results demonstrate the progress we're making in improving the growth and operating profile of our business, putting us within reach of sustainable profitability and cash generation. At the same time, we are building on Exagen's leadership in autoimmune diagnostics through continued investment in clinical evidence generation, pipeline innovation and AI-powered tools that support rheumatology workflows to strengthen our role in rheumatology decision-making.”
Next report
Nov 3, 2026 (In 3 weeks)Revenue estimate$18.3M
EPS estimate-$0.19
Valuation & ratios
Valuation
as of 10/09/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Exagen Inc. report Q2 2026 earnings?
- Exagen Inc. (XGN) reported Q2 2026 earnings on August 4, 2026 before market open.
- What were Exagen Inc.'s Q2 2026 revenue and EPS?
- Exagen Inc. reported revenue of $19.9M and eps of $-0.13 for Q2 2026.
- Did Exagen Inc. beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $17.8M by $2.1M. EPS beat the consensus estimate of $-0.19 by $0.06.
- How did Exagen Inc.'s Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 15.9% from $17.2M a year earlier and eps grew 27.8% from $-0.18.
- Where can I find Exagen Inc.'s Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001274737-26-000047) and the 10-Q periodic report (0001274737-26-000048) directly on SEC EDGAR. The filing index links above go to sec.gov.
